Jun
25

Medicare physician reimbursement increase passes

Yesterday the House passed legislation increasing Medicare physician reimbursement till November 30, when it is slated to drop by 23%. Then, barely a month later, physicians will see another cut which will cut their pay by another seven points.
The temporary fix will increase payments by just over two percent.
For six months.
Then the whole debacle/fiasco/mess will resurrect it’s ugly head and we’ll be right back where we are today, except the cost of an ultimate fix will then be close to $300 billion.
But that will happen after the fall elections, and well before the 2012 voting season starts.
On the workers comp side, several states will see their doc fee schedules change in step with Federal reimbursement, while the impact on most jurisdictions’ fee schedules will play out over time as regulators and legislators work thru the politically-charged process, alter conversion factors and assess their potential impact on access and cost.
The indirect impact is likely to be much more significant as physicians and other providers billing CPT codes seeking to maximize reimbursement from private payers to offset (inflation adjusted) losses in revenue from the Feds.
For those interested in more detail, click here.


Jun
25

Friday’s news – Stranger than reality TV

Newsday broke a story yesterday about a former Islip, NY parks workers who was busted for insurance fraud.
But this isn’t your typical “out on TTD, moonlighting as a handyman” gig.
Nope, John Livingston, out of work due to a comp injury and according to his statements to his employer and adjuster, unable to find employment, was allegedly working as a bouncer at a bar.
A nude bar.
It seems that the $17 grand Livingston collected so far wasn’t enough to sustain his lifestyle and other obligations, so a man’s got to do, what a man’s got to do. In this case, what Mr Livingston had to do was ensure patrons didn’t get unruly or obstreperous. Let’s think about this. Livingston, who was employed as an automotive equipment operator, told the Town he couldn’t work in that job, yet he was able to find work tossing potentially beefy, probably inebriated guys out of a ‘gentleman’s’ club.
Livingston’s previous job must’ve been much more strenuous than your typical truck driving gig, or perhaps he couldn’t sit for long hours, yet could, without too much pain or chance for injury exacerbation, latch onto struggling guys and launch them thru the back door.
Or maybe this was part of his therapy and work conditioning program.
Livingston pled not guilty.
The Empire State has gotten rather forceful about comp fraud, so I’d expect Mr Livingston will come to regret his alleged decision to mess with the system.
Hats off (no pun intended) to the adjuster or employer who ordered the investigation (if in fact this was the result of surveillance) and busted Mr Livingston.


Jun
22

Utilization review – A payer’s ethical responsibility

Yesterday’s post about Mass General’s mishandling (to be kind) of a woman’s procedure and reimbursement thereof elicited a thoughtful email from the former CEO of a major work comp insurer.
Here’s what he said (identifying details removed to protect the source).
I got in trouble early on with (the payer’s) UR staff and attorneys because (after giving them multiple direct orders to clean up pre-auth letters) I began directing them to pay for procedures they approved but later wanted to deny. They would simply say that the procedure was appropriate for the injury but NEVER check the claim to see if it was part of the approved injury. For instance, they would approve a shoulder surgery as medically appropriate but the injury was for a knee. Had they checked the claim they would have seen the shoulder was not covered. Regardless, the UR folks approved it in pre-auth and the surgery was done.
Only afterwards, when the bill came in and the claims rep denied it did UR look at the claim more closely and support the adjuster. UR’s excuse was that in very small lettering at the bottom of the page it said that we (the payer) may not be liable if blah blah blah. I told them that was execrable and to clean up the process and language. For too long, the UR department did not and so I made them pay the claims and docked them in their evaluations.
If the doc and the patient did everything they were supposed to and got an OK in writing I felt it was the carrier’s ethical and moral responsibility to pay regardless of what the lawyers said.
Hear hear.
I’m of the opinion that this happens more frequently than one might surmise, but these types of determinations are kept quiet so as to not motivate more requests for treatment on non-covered body parts/conditions.
I’d also surmise that many non-approved treatments get paid due to the lack of an automated electronic connection between UR and bill review/claims. This is also an ethical issue of high importance, as it is a failure to act as a responsible fiduciary.
What does this mean for you?
How does your company handle these issues, and how do you feel about that?


Jun
18

Broadspire’s the first

Broadspire, one of the largest TPAs in the country, has announced a new network strategy which goes by the acronym BOLD, that is notable as much for what’s missing than what’s present.
There’s no mention of Coventry in the list of Broadspire’s network partners.
I’ve discussed this at length with Danielle Lisenby, Broadspire’s top managed care exec, and the company’s president, Ken Martino. Danielle, Ken, Medical Director Jake Lazarovic, MD have led the company’s efforts to develop and implement a medical management strategy based on “a better answer than the same old broad based discount network ” approach.
Martino sees the BOLD network as a differentiator for Broadspire, a unique solution that is clearly different from those offered by the company’s competitors. Martino also noted that the extensive analysis conducted by Broadspire confirmed their belief that “greater savings could be obtained using multiple partners than relying primarily on one network.”
I’ve seen the analysis, and the numbers support the company’s assertion. When examining network penetration and net savings percentage, the new strategy provides better results in all but three states, and in those the difference is minimal.
On the flip side, the net increase (penetration x savings) in many states increases by mid-single digits, with a couple well over ten percent.
Sources outside Broadspire indicate Coventry is none too happy with Broadspire’s decision. According to Coventry reps (albeit second hand), Broadspire wasn’t willing to ‘partner’ with Coventry. I’ll leave it to readers to puzzle out how exactly Coventry defined ‘partner’.
What does this mean for you?

Coventry dominates the work comp PPO business.
They are, far and away, the leader in market share, and use that position to their advantage. Since the exclusive marketing deal with Aetna was inked a couple years ago, Coventry has been raising network access prices and strongly encouraging customers to utilize their network in most, if not all, jurisdictions.
From a business strategy, this makes a lot of sense – from Coventry’s perspective. Using market clout to drive higher margins and hold off competitors is just good business – for the market leader. Over the near term, this has paid dividends for the work comp division’s parent, as the network operation has generated significant cash flow.
I’d highlight ‘over the near term’. Over the longer term, Coventry’s approach is bound to alienate payers looking for more flexibility, more control over their medical spend. As it is, payers utilizing the ‘one network’ approach are ceding a significant amount of control over the largest part of the claims dollar to an entity that makes money on medical bills – the more bills that are generated, the more money they make.
Even a non-actuary like myself can see the problem – for the payer – with that business model. Now Broadspire has become the first large payer to break away entirely from the Coventry model. Their numbers are compelling; it will be interesting indeed to watch how self-insured employers react.
Note – there are several other large payers also looking deeply into new medical management strategies. Perhaps Broadspire’s move will push these efforts along.


Jun
17

Regulation, Legislation, and Unintended Consequences

I attended a meeting of work comp insurance execs in DC yesterday that addressed, among other topics, the dynamic situation in Texas, fee schedules for drugs, pending Federal legislation and the potential impact on comp, and the Gulf oil spill and its potential ramifications for Jones Act and Longshore/Harbor workers coverages.
While there wasn’t a common theme (beyond the obvious) at the outset, by the end of the morning I was struck (as were several others in attendance) by the unintended consequences of past actions, and potential adverse consequences of future legislation and regulation.
As an example.
California slashed the work comp pharmacy fee schedule just about in half six years ago. Since that time, the number of scripts per claimant has increased 25% and costs per claimant are up 31% (CWCI stats). And that’s not the worst of it. Schedule II narcotics have gone from less than one percent of scripts to almost six percent, a six-fold increase.
Why? How could costs go up if the fee schedule cut prices so deeply?
Simple. Some bad actors figured out how to game the system by repacking drugs and inventing their own prices, prices that were several times higher than they should have been. OK, that was fixed, albeit several years, and several hundred million dollars, later.
But there’s another problem, one highlighted by the huge growth in narcotic dispensing – PBMs could not afford to effectively manage the drugs dispensed to claimants.
PBMs make their margin on the delta between what payers pay the PBM for scripts and what the PBM pays the pharmacy. When that delta is negative, as it is in California, there isn’t any money to pay for data mining to identify potentially problematic prescribers; pharmacies that have low generic fill rates; claimants taking multiple narcotics and/or other meds that may conflict with those narcotics. And if they can identify the issues, they can’t pay pharmacists and physicians to review medical records, contact the treating physician, discuss the issues, and resolve any disagreement.
Sure, PBMs and payers could decide to operate on a cost-plus basis, but there are business reasons payers prefer bundled pricing – its easier to assign it to a file, simpler to administer, and easier to report to clients and regulators.
That’s not to say all PBMs don’t try to clinically manage claimants’ drugs – many do, and do a pretty good job given their severely limited resources. The payers that operate in multiple jurisdictions know that the PBM’s fees in other states subsidize their California drug spend…and as long as California is the only state with a catastrophically low pharmacy fee schedule, that’s OK (unless you’re a California only payer, in which case good luck finding a PBM that will handle your pharmacy at fee schedule). But if other states decide to use a similarly low fee schedule, the wheels fall off the system.
This is but one example of unintended consequence of a seemingly obvious and easy way to reduce comp costs – costs actually increased dramatically, and I’d argue that length of disability did as well for those claimants on narcotics that otherwise would not have been.
The pending sunset of pharmacy networks in Texas is another example; due to the wording of Texas’ comp reform legislation (as interpreted by the decision makers in Texas), PBMs can’t operate in the state after 12/31/2010. There’s a good bit of activity in Austin as various entities attempt to resolve this situation before the end of the year, and there’s some hope those efforts will be successful. That said, there’s no question a lot of work is being done by a lot of people who are tasked with cleaning up the ‘unintended consequence’ of unfortunately-worded legislation.
What does this mean for you?
As some smart person said years ago, “What makes you think you’ll have time to fix it if you don’t have the time to do it right to begin with”. Lest readers construe this as a ‘blame the regulator/legislator’ rant – it isn’t. Rather, stakeholders must engage with the people tasked with addressing these issues – before the laws are passed and regulations written. And yes, regulators and legislators would be well served to listen to those who live these issues every day.


Jun
15

Work comp pharmacy fee schedules – what’s the answer

The evidence is pretty clear – low fee schedules don’t have much, if any, impact on drug costs. Sure, they give the appearance of action, and some actuaries and politicians are able to claim future cost reductions based solely on slashing drug fee schedules from some multiple of AWP to some fraction of AWP, or perhaps even a state’s Medicaid rate. But the data – whether from NCCI, CWCI, or my own firm’s surveys, suggest that the price per pill (with some notable exceptions) is much less important in the scheme of things than how many and what type of pills are dispensed to claimants.
Exhibit One is CWCI’s recent analysis of drug costs post implementation of MediCal as the basis for the work comp fee schedule. Alex Swedlow (one of the best and brightest analysts in the business) and John Ireland’s analysis found “significant post-reform growth in both the average number of prescriptions and the average payments per claim for prescription medications. Between calendar years 2005 and 2007, the number of prescriptions per claim in the first year following a work injury increased 25 percent, while first-year pharmaceutical payments per claim increased 36 percent.” [emphasis added]
Yes, after slashing the fee schedule from AWP+40% for generics and AWP+10% for brand (plus dispensing fees) to something closer to AWP-50% Generic /AWP-20% Brand, drug costs per claim went up. A lot. But that’s not the worst of it.
The biggest percentage gainer? Schedule II narcotics – the heavy-duty stuff, associated with significant risk of addiction and abuse – went from less than one percent of scripts to almost six percent – a 600% jump in three years.
Why? One theory, which I’ve tested in conversations with several clinical pharmacists, is the drastic decrease in reimbursement in the Golden State left PBMs with no funds to do any real Drug Utilization Review (DUR), and even less to intervene on potentially high-cost, high-impact claims. PBMs make their money on the delta between what they charge the payer and what the retail pharmacy charges them; in almost all cases, PBMs’ retail contracts call for reimbursement above the CA MediCal rate.
Tough to make that up on volume…
I’m meeting with interested folks in DC tomorrow to discuss this issue, and perhaps to think thru some potential alternatives to AWP, or God forbid, Medicaid as the basis for comp Rx fee schedules.
And as I prepare for the conversation, I’m thinking that a fee schedule based on Usual and Customary has some appeal.
U&C in pharmacy is the cash price for that drug on that day at that pharmacy; think $4 for the long list of generics pioneered by Walmart (which, by the way, is lower than what Walmart charges comp PBMs for the same drugs). Unlike other U&Cs, it is tougher to game, can be reported and collected electronically, and bears some relevance to market price – unlike AWP, which is known as ‘Ain’t What’s Paid’ as it doesn’t factor in rebates, volume discounts, and other price-reducing mechanisms. True work comp drug geeks will know that 33 states currently use AWP as the basis for their fee schedules.
U&C isn’t perfect – any time you base reimbursement on a rate that can be set by the payee, you open yourself up to abuse. But risk of abuse or gaming is likely pretty low – pharmacies see very few work comp scripts, and aren’t likely to play games with their cash price customers just to make a few more bucks on a comp patient. And pharmacy chains do tend to alter pricing to respond to market demands, making U&C at least somewhat credible.
Perhaps best of all, U&C is going to be around for the long term – unlike the version of AWP that is most popular which will disappear within a year.


Jun
14

Why don’t comp payers change?

I was talking at length with a good friend who works for a large payer last week, discussing the process of getting the organization to make significant, and very much needed, improvements to their managed care program.
This got me thinking – by no means is this situation unique to that one payer. If anything, resistance to change is a consistent thread throughout the workers comp payer/buyer/service industry. Pondering this over the weekend I came up with a few warning signs of and reasons for the resistance.
Warning signs
Statements such as “we’ve always done it that way”, “that’s our policy”, or “that’s how we handle X here” can indicate pride and consistency, traits that are often excuses for not thinking more and deeper about specific issues. Policies are good, as long as they’re ruthlessly examined under a very bright light on a regular basis.
Long, exhaustive, exhausting studies and analyses and research into a new idea, especially those that involve a large committee of folks with lots of other, higher priorities. Committees are where good ideas go to die.
A culture of fear, where junior staff wait to hear what the boss says before chiming in; where criticism is pointed and personal, where people are afraid to speak up for fear of being criticized or chastised.
A resistance to comparison and measurement, where managers seek to report the data that demonstrates positive results (or at least results that help them achieve their bonus targets) and don’t look for ways to compare their performance to competitors or the industry as a whole.
Why?
There is a cultural issue in comp, and perhaps in the larger property and casualty industry that has significant negative influence on the ability of companies to evolve and improve.

People who say ‘no’ succeed; risk-takers do not.
Risk takers seek to write the somewhat questionable policies, try different approaches, ask ‘why not’ instead of ‘why’, look for creative solutions to old intractable problems, seek answers outside the industry instead of always relying on the time-tested. Sure, these risk-taking efforts aren’t always, or even often, game-changing successes, but occasionally they do work brilliantly, and even when the improvement is incremental, it is improvement.
The ‘no’ people don’t write the risks that fail to meet every criterion, stick to the book when ‘managing’ claims, don’t direct injured workers in states that don’t provide explicit authority, complain that the laws don’t support tougher stances. They don’t look for the ‘how to’, they complain about the ‘why not’.
More specifically, there’s a financial gravy train that drives TPAs and insurers that makes it difficult to try new approaches in managed care.
That gravy train is fueled by managed care fees
, fees that in many cases are larger than the earnings from claims administration, and can represent a big chunk of an insurer’s profit margin. Fees, whether from case management, utilization review, bill review, networks, or other services, contribute to the overall organization’s financial results, making it tough to consider programs that might actually reduce the amount ‘earned’ by managed care programs.
Never mind that these new programs will also reduce medical costs. In fact, I can, and often have, made the argument that the current large generalist PPO reimbursed on a percentage-of-savings basis is actually driving up workers comp medical expenses, and the data I’ve seen bears that out.
Yet the vast majority of payers are still wedded to this old model.
What does this mean for you?
More evidence that change in the comp industry, however much it is needed, will be difficult and frustrating. Precisely because of that difficulty, those organizations that adapt and evolve will find themselves better positioned than their moribund competitors.


Jun
10

Can the surgical implant problem be fixed?

According to Bill Kidd’s piece [sub req] in WorkCompCentral this morning, several states are attempting to address the rapidly growing problem of surgical implant device fees via regulation or legislation – by basing reimbursement on the manufacturer’s invoice. While it is great to see authorities paying attention to what has been a big problem for comp payers for several years, this solution may not be much of a…solution.
As I noted in a post a couple weeks ago;
“In several jurisdictions (including NY TX CA (working on a change) and FL) the basis for reimbursement is some version of the “documented paid amount” plus a handling fee of 10% or so up to a cap of a few hundred dollars (CA) or a percentage of the invoice amount (FL). Illinois is also contemplating a similar arrangement. [Bill notes that Minnesota is also looking into a fix]
The problem lies in the documentation of the paid amount. Most payers ask for a copy of the invoice, which, on the surface, makes sense – this is what was paid.
Not exactly. What the invoice doesn’t show can include:
– volume purchase discounts
– rebates
– “3 for the price of 2″ deals
– waste (some surgeons use the cage from one kit and screws from another, so the payer is paying for more hardward than is actually being used)
– internally developed invoices (documents prepared not by the supplier but by the provider)
This last point is the crux of the issue. Hospital systems often buy in bulk, with several implant kits shipped and billed; this obviously makes it impossible for the provider to produce the invoice for the device used in a specific surgery, as they never got one. Thus, many providers develop the invoice for a specific implant kit themselves.”
So, what to do?
I don’t see a legislatively-simple solution, or rather one that only requires a revision to existing fee schedule language. Requiring providers to disclose the ‘price’ is only practicable if they know what that ‘price’ is; as noted above, that often is difficult if not impossible to establish.
What states can do is require reimbursement at ‘cost’ plus something, allowing payers to work with specialty bill review vendors to determine what that ‘cost’ is. (HSA Client) FairPay Solutions provides this service; if there are others out there that can assist, let me know.
predictive modeling
And
artificial intelligence


Jun
2

News from North Dakota – some good, some weird

Three items of interest from North Dakota – one quite positive, the others puzzling at best.
First, the good.
Sandy Blunt, former CEO of the NoDak work comp insurance fund, gave an excellent presentation on the current state of the work comp industry, with a strong focus on which claims are most important and most deserving of attention, and why they’re also the ones often missed. (I’ve been privileged to work with Sandy on several projects, and the presentation is a great example of how much value he brings.)
If you missed it (over 600 attended the webinar), the recording is here and the slides here. (use FINEOS as password, all caps)
Now, onto the weird. And yes, both also involve Mr Blunt.
Regular readers will recall Sandy appealed his conviction (on ridiculous charges) to the North Dakota Supreme Court fifteen months ago, with oral arguments heard seven and a half months ago. As of yesterday, the Supreme Court had not yet seen fit to issue a ruling in the case.
One has to ask why.
Dozens of cases that were filed and argued after Blunt’s have been decided and those decisions released. The evidence is in, the arguments have been heard, there has been plenty of time for clerks to research precedents and judges to confer.
Yet no decision has been announced. Why not?
Even stranger, the prosecutor responsible for the conviction, Cynthia Feland, continues her electoral campaign for judge despite ratings from the North Dakota Bar Association that are lower than any other candidate. Perhaps the members of the Bar in NoDak are aware of some of Feland’s…issues.
Members of the ND State Bar Association were asked to rank, on a scale of one to five, the qualifications of attorneys running in contested state judicial elections’ professional competence, legal experience, judicial temperament, integrity and overall qualification.
Feland ranked lowest in every single category. Every one. And she was ranked lowest overall as well, with a 2.83 out of 5.00.
With the primary election scheduled for June 8 (a week from yesterday), Feland is hoping to be one of the top two vote-getters, a distinction that would put her into the general election in November.
Perhaps the Supreme Court is waiting on the results of the primary before announcing their decision. If that is the case, it is indeed unfortunate that politics would play any role in the judicial process.
If that isn’t the reason for this close-to-record delay, than what is?


Jun
1

Florida’s (repackaged) drug problem

Mike Whitely of WorkCompCentral’s article [sub req] on Florida Governor Charlie Crist’s veto of the bill limiting reimbursement for physician-dispensed repackaged drugs illustrates just how confusing the weird world of work comp can be to the uninitiated – like Mr Crist.
For those unfamiliar with repackaged drugs, here’s a quick primer.
First, recall drug costs in comp are driven more by utilization than by price, except in instances like this where price gouging is rampant.
Work comp drug fee schedules peg the amount paid for drugs to a multiple of AWP (except CA, which uses Medi-Cal); Florida’s is set at 100% of AWP plus a $4.18 dispensing fee for both generics and brand drugs. (As I’ve noted previously, there are major issues with the use of AWP.) But AWP is based on the drug’s NDC number, a code that can be created by the wholesaler. Thus, if a company wants to buy a million 800 mg ibuprofen tablets and repackage them into lots of 27, it can create it’s own NDC, and thus set its own AWP.
CWCI (California) research showed that the repackaged drug ranitidine (generic Zantac) was priced at $255.56 for 150 mg. pills, compared to a retail pharmacy’s cost of $25.90 and Drugstore.com’s $19.71; the difference in markup on the ingredient cost between physician dispensing and pharmacy dispensing was about 1700%. Naproxyn (Aleve) markup averaged 1000%, Vicodin 750%.
Since California figured out how to prevent entrepreneurs making a fortune by repackaging drugs, the repackagers moved into other states. Florida is the current target; the latest Survey of Prescription Drug Management in Workers Comp indicated this is also a big problem in the upper midwest and southwest. Some states, including Texas and New York, specifically prohibit physician dispensing.
Florida’s drug costs were recently analyzed by WCRI, which reported:
“…the average payment per claim for prescription drugs in Florida’s workers’ compensation system was $565–38 percent higher than the median of the study states.
The main reason for the higher prescription costs in Florida was that some physicians wrote prescriptions and dispensed the prescribed medications directly to their patients. [emphasis added] When physicians dispensed prescription drugs, they often were paid much more than pharmacies for the same prescription.
The WCRI study, Prescription Benchmarks for Florida, found that some Florida physicians wrote prescriptions more often for certain drugs that were especially profitable. For example, Carisoprodol (Soma®, a muscle relaxant) was prescribed for 11 percent of the Florida injured workers with prescriptions, compared to 2 to 4 percent in most other study states.
Financial incentives may help explain more frequent prescription of the drug, as the study suggested. The price per pill paid to Florida physician dispensers for Carisoprodol was 4 times higher than if the same prescription was filled at pharmacies in the state. [emphasis added]
The study reported that the average number of prescriptions per claim in Florida was 17 percent higher than in the median state. [emphasis added] Similar results can be seen in the average number of pills per claim.”
Physician dispensing is not all bad; there’s something to be said for ensuring the patient receives the right drug on the way out of the office, improving compliance and reducing the patient’s hassle factor.
Crist, who is going to be running as an Independent for re-election this fall, may have bowed to pressure from lobbyists working for physicians and repackagers. He certainly wasn’t trying to ingratiate himself with business; several larger employers were reportedly behind the measure.

So, what do you do about this?

Some payers are rewriting their provider contracts to specifically ban physician dispensing. Others are unilaterally cutting reimbursement to the ‘non-repackaged’ level. Another tactic is to notify contracted physicians that no new patients will be directed to them if they bill for repackaged drugs.
As Florida is an employer-direction state, payers have a lot of control and influence over physicians.
Use it.